Abstract
Turoctocog Alfa (Novoeight®), a recombinant factor Ⅷ(rFⅧ), was approved in China in 2021. Product X is the most commonly used rFⅧ product among Chinese patients with haemophilia A. This study was to compare the annual cost between these two products as prophylaxis treatment for paediatric and adult patients with severe haemophilia A from the Chinese healthcare perspective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
